| 1 |
34273686 | Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting "substance P-hepatic stellate cells-hepatocellular carcinoma" axis. | 2021 Sep |
1 |
| 2 |
32106373 | MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc. | 2020 May |
2 |
| 3 |
30615851 | ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells. | 2019 Feb |
1 |
| 4 |
31092810 | Doxorubicin-Induced Cancer Cell Senescence Shows a Time Delay Effect and Is Inhibited by Epithelial-Mesenchymal Transition (EMT). | 2019 May 16 |
1 |
| 5 |
29581735 | Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator. | 2018 Apr |
1 |
| 6 |
27932314 | TIS21/BTG2 inhibits doxorubicin-induced stress fiber-vimentin networks via Nox4-ROS-ABI2-DRF-linked signal cascade. | 2017 Jan |
1 |
| 7 |
28260043 | Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma. | 2017 Apr |
1 |
| 8 |
28476800 | Heterogeneous Cell Types in Single-cell-derived Clones of MCF7 and MDA-MB-231 Cells. | 2017 May |
2 |
| 9 |
28627650 | The inhibitory effects of deep-sea water on doxorubicin‑induced epithelial-mesenchymal transition. | 2017 Aug |
1 |
| 10 |
28972876 | miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. | 2017 Sep |
1 |
| 11 |
27126361 | ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition. | 2016 Jul 28 |
1 |
| 12 |
27350211 | Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. | 2016 Sep |
1 |
| 13 |
27398136 | miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. | 2016 |
1 |
| 14 |
27755958 | SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line. | 2016 Sep 30 |
1 |
| 15 |
28335269 | Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma. | 2016 Jul 30 |
2 |
| 16 |
26690867 | Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells. | 2015 Sep |
2 |
| 17 |
24405590 | [Expression and significance of FGFR2IIIc in chemoresistant bladder cancer cells]. | 2014 Jan |
1 |
| 18 |
24612689 | Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells. | 2014 Apr |
2 |
| 19 |
23128467 | N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells. | 2013 Jan |
1 |
| 20 |
19898866 | Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. | 2010 May |
1 |
| 21 |
14555241 | Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. | 2003 Oct 15 |
1 |
| 22 |
11550207 | Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. | 2001 Sep 15 |
1 |
| 23 |
11712680 | Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy. | 2001 |
4 |
| 24 |
7880731 | Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. | 1995 Mar |
2 |
| 25 |
1382837 | Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. | 1992 Oct 1 |
2 |
| 26 |
1384135 | Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen. | 1992 Feb |
1 |